Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q2 2013 · 10-Q
Revenue$0.00$0.00— vs Q2 2012 Net Income-$3.11M-$3.11MN/M vs Q2 2012 EPS Diluted-$0.03-$0.03N/M vs Q2 2012 Operating Income-$1,913,527N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
derived
ended Jun 30, 2013 · filed Aug 12, 2013 · 43 d after period end